Thozalinone

Thozalinone is a stimulant that was developed in the 1960s as a medication for depression and obesity. It is a cognitive enhancer and dopaminergic stimulant, which means it increases the activity of the neurotransmitter dopamine in the brain. Thozalinone was developed by the pharmaceutical company Upjohn (now part of Pfizer) but is no longer marketed.

Pharmacology

Thozalinone works by inhibiting the reuptake of dopamine, which increases the amount of dopamine in the brain. This can lead to increased alertness, attention, and motivation, as well as decreased fatigue and appetite. Thozalinone is structurally related to other stimulants like amphetamine and methylphenidate, but it is not a controlled substance in most countries.

Medical uses

Thozalinone was originally developed for the treatment of depression and obesity. However, it is no longer marketed for these uses. It has been studied for potential use in the treatment of attention deficit hyperactivity disorder (ADHD), but it is not currently approved for this use.

Side effects

Like other stimulants, thozalinone can cause side effects such as insomnia, anxiety, agitation, and increased heart rate. It can also cause psychosis in some individuals, especially at high doses or in those with a history of mental illness.

See also

• List of stimulants
• List of antidepressants
• List of obesity medications

Thozalinone Resources
Latest articles Most recent articles Ongoing trials	Wikipedia